Results 21 to 30 of about 9,613 (181)
Frontiers in Immunology, 2018 Cellular protection against undesired effects of complement activation is provided by expression of membrane-bound complement regulatory proteins including CD59.
Laura A. Michielsen +7 more
doaj +1 more source
Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59 [PDF]
Multiple Sclerosis Journal, 2018 Background: CD59, a broadly expressed glycosylphosphatidylinositol-anchored protein, is the principal cell inhibitor of complement membrane attack on cells. In the demyelinating disorders, multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), elevated complement protein levels, including ...
Wioleta M Zelek +9 more
openaire +4 more sources
Molecular pathogenesis of human CD59 deficiency [PDF]
Neurology Genetics, 2018 To characterize all 4 mutations described for CD59 congenital deficiency.The 4 mutations, p.Cys64Tyr, p.Asp24Val, p.Asp24Valfs*, and p.Ala16Alafs*, were described in 13 individuals with CD59 malfunction. All 13 presented with recurrent Guillain-Barré syndrome or chronic inflammatory demyelinating polyneuropathy, recurrent strokes, and chronic hemolysis.
Karbian, Netanel +7 more
openaire +2 more sources
Bioorthogonal Tools for Ethanolamine Lipids and Protein Conjugates
Angewandte Chemie, EarlyView.An alkyne‐tagged ethanolamine analog (AlkEA) enables bioorthogonal, metabolic labeling of endogenous phosphatidylethanolamine (PE) and its protein modifications. AlkEA is incorporated into PE via the Kennedy pathway, allowing CuAAC‐based visualization of PE and affinity capture of PE‐conjugated LC3, ubiquitin, and GPI‐anchored proteins.
Yuan‐Ting Cho +5 more
wiley +2 more sources
Complement Terminal Pathway Activation is Associated with Organ Failure in Sepsis Patients
Journal of Inflammation Research, 2022 Fatima M Ahmad,1,2 Maysaa’ A Al-Binni,2 Amjad Bani Hani,3 Mahmoud Abu Abeeleh,3 Anas HA Abu-Humaidan1 1Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, The University of Jordan, Amman, Jordan; 2Department of the Clinical ...
Ahmad FM +4 more
doaj
Cancer Cell International, 2019 Background T-acute lymphoblastic leukemia (T-ALL) was a hematological malignancy characterized by the accumulation of immature T cells in bone marrow and peripheral blood.
Yanfei Jia +9 more
doaj +1 more source
Structural basis for membrane attack complex inhibition by CD59
Nature Communications, 2023 CD59 protects human cells from damage by the MAC immune pore. The authors show how CD59 inhibits MAC, by deflecting pore-forming β-hairpins of complement proteins.
Emma C. Couves +6 more
doaj +1 more source
Defining the CD59-C9 Binding Interaction [PDF]
Journal of Biological Chemistry, 2006 CD59 is a membrane glycoprotein that regulates formation of the cytolytic membrane attack complex (MAC or C5b-9) on host cell membranes. It functions by binding to C8 (alpha chain) and C9 after their structural rearrangement during MAC assembly. Previous studies indicated that the CD59 binding site in C9 was located within a 25-residue disulfide-bonded
Yuxiang, Huang +4 more
openaire +2 more sources
Cell Reports, 2013 Pore-forming proteins containing the structurally conserved membrane attack complex/perforin fold play an important role in immunity and host-pathogen interactions.
Steven Johnson +4 more
doaj +1 more source
An update on the CD59 blood group system [PDF]
Immunohematology, 2019 Abstract This update of the CD59 blood group system (Weinstock C, Anliker M, von Zabern I. CD59: a long-known complement inhibitor has advanced to a blood group system. Immunohematology 2015;31:145–51) increases the number of reported patients with CD59 deficiency from 10 to 14.
Weinstock, C. +2 more
openaire +2 more sources